certolizumab pegol vs infliximab-qbtx (Ixifi)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT00552344 · Phase 3 · completed
This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)
Result source: NCT00552058
infliximab-qbtx (Ixifi)
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | infliximab-qbtx (Ixifi) |
|---|---|---|
| Clinical remission (induction) | 31.6% vs 25.4%+6.2 vs placeboNCT005520582 other results
| —Not reported |
| Endoscopic response (induction) | —Not posted · NCT00152425 | —Not reported |
| Clinical remission (maintenance) | 37.5% vs 35%+2.5 vs placeboNCT003564081 other result
| —Not reported |
| Endoscopic response (maintenance) | —Not posted · NCT00152425 | —Not reported |
Clinical remission (induction)
- certolizumab pegol
- 31.6% vs 25.4%+6.2 vs placeboNCT00552058
2 other results
- 26.5% vs 19.1% NCT00552058
- 23.3% vs 15.8% NCT00552058
- infliximab-qbtx (Ixifi)
- —Not reported
Endoscopic response (induction)
- certolizumab pegol
- —Not posted · NCT00152425
- infliximab-qbtx (Ixifi)
- —Not reported
Clinical remission (maintenance)
- certolizumab pegol
- 37.5% vs 35%+2.5 vs placeboNCT00356408
1 other result
- 3% vs 35% NCT00356408
- infliximab-qbtx (Ixifi)
- —Not reported
Endoscopic response (maintenance)
- certolizumab pegol
- —Not posted · NCT00152425
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-qbtx (Ixifi): no structured comparison results are available for Crohn's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. certolizumab pegol: 4 of 4 rows · infliximab-qbtx (Ixifi): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol |
|---|---|
| Dropout rate | 78.4%a NCT00552344 · Phase 3 · monotherapy show 24 more results80.3% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 69.5%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 92.3% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 7.2% NCT00552058 · Phase 3 · monotherapy 40.4%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 46.2%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 53.3%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 25%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 3.1%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT00552344 · Phase 3 · monotherapy show 24 more results35.8% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 18.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 51% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 3.6% NCT00552058 · Phase 3 · monotherapy 14.6%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence —400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence —400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 12.5%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence —400 mg NCT00291668 · Phase 2 · registry result, not featured evidence —200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 37.1%a NCT00552344 · Phase 3 · monotherapy show 24 more results40.3% NCT00160524 · Phase 3 · monotherapy 13.4%400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy 13.4%400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 31.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 44.5% NCT00160706 · Phase 3 · monotherapy 14.6%400 mg NCT00356408 · Phase 3 · monotherapy 0%CDP870/Completer NCT00356408 · Phase 3 · monotherapy 12.1%CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 5.4% NCT00552058 · Phase 3 · monotherapy 38.2%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 40%High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 0%Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 50%Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 23.1%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 33.3%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 31.3%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 9.4%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a crohn's disease 31.6% abdominal pain 18.7% upper respiratory tract infection 15.7% NCT00552344 · Phase 3 · monotherapy show 21 more results400 mg every 2 weeks nasopharyngitis 17.2% pyrexia 11.8% arthralgia 10.8% NCT00308581 · Phase 3 · monotherapy 400 mg every 4 weeks headache 16.6% nasopharyngitis 12.3% nausea 11.2% NCT00308581 · Phase 3 · monotherapy 400 mg nasopharyngitis 27.5% headache 20.5% pyrexia 20.5% NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 400 mg crohn's disease 21.4% (placebo 7.1%) arthralgia 18.4% (placebo 0%) upper respiratory tract infection 13.6% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy arthralgia 25% (placebo 0%) myalgia 18.8% (placebo 0%) sinusitis 18.8% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy crohn's disease 33.3% (placebo 7.1%) arthralgia 21.2% (placebo 0%) nausea 18.2% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy headache 5.4% (placebo 4.7%) abdominal pain 4.5% (placebo 3.7%) arthralgia 4% (placebo 2.8%) NCT00552058 · Phase 3 · monotherapy 400 mg headache 33.7% arthralgia 30.3% nasopharyngitis 23.6% NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 High-dose (Weight Adjusted) abdominal pain upper 40% nasopharyngitis 20% nausea 20% NCT01190410 · Phase 2 · registry result, not featured evidence Low-dose (Weight Adjusted) asthma exercise induced 25% cough 25% dizziness 25% NCT01190410 · Phase 2 · registry result, not featured evidence Re-Induction abdominal injury 50% anal fissure 50% c-reactive protein increased 50% NCT01190410 · Phase 2 · registry result, not featured evidence 400 mg / 200 mg pyrexia 46.2% (placebo 11.1%) nasopharyngitis 38.5% (placebo 55.6%) contusion 15.4% (placebo 0%) NCT00329420 · Phase 2 · registry result, not featured evidence 400 mg / 400 mg nasopharyngitis 40% (placebo 55.6%) pyrexia 20% (placebo 11.1%) nausea 13.3% (placebo 5.6%) NCT00329420 · Phase 2 · registry result, not featured evidence nasopharyngitis 20% (placebo 22.2%) nausea 13.3% (placebo 22.2%) urinary tract infection 13.3% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence nasopharyngitis 62.5% (placebo 22.2%) dna antibody positive 12.5% (placebo 22.2%) headache 12.5% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.9% (placebo 31.3%) nausea 6.3% (placebo 3.1%) pharynx discomfort 6.3% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 23.3% (placebo 31.3%) nausea 6.7% (placebo 3.1%) pharyngolaryngeal pain 6.7% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 19 more results
show 19 more results
show 1 more result
show 17 more results
show 17 more results
show 2 more results
+ 28 further endpoints in the CSV export.
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT02326272 · Phase 3 · completed
This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16; Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo). (met)
Result source: NCT02326298
infliximab-qbtx (Ixifi)
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | infliximab-qbtx (Ixifi) |
|---|---|---|
| PASI 75 | 82.6% vs 11.6%+71 vs placeboNCT0232627211 other results
| —Not reported |
| PASI 90 | 55.4% vs 4.5%+50.9 vs placeboNCT0232627211 other results
| —Not reported |
| PASI 100 | —Not posted · NCT04123795 | —Not reported |
| sPGA 0/1 | 57.9% vs 4.2%+53.7 vs placeboNCT023262985 other results
| —Not reported |
| DLQI, change | -10 vs -3.8−6.2 vs placeboNCT023262725 other results
| —Not reported |
PASI 75
- certolizumab pegol
- 82.6% vs 11.6%+71 vs placeboNCT02326272
11 other results
- 75.8% vs 6.5% NCT02326298
- 66.7% vs 5% NCT02346240
- 87.1% vs 7.9% NCT03051217
- 81.4% vs 11.6% NCT02326272
- 66.5% vs 6.5% NCT02326298
- 61.3% vs 5% NCT02346240
- 73% vs 7.9% NCT03051217
- 74.7% vs 3.8% NCT02346240
- 68.2% vs 3.8% NCT02346240
- 82.8% vs 6.8% NCT00245765
- 74.6% vs 6.8% NCT00245765
- infliximab-qbtx (Ixifi)
- —Not reported
PASI 90
- certolizumab pegol
- 55.4% vs 4.5%+50.9 vs placeboNCT02326272
11 other results
- 43.6% vs 0.4% NCT02326298
- 49.1% vs 0.3% NCT02346240
- 34% vs 0.2% NCT02346240
- 75.7% vs 0.2% NCT03051217
- 52.6% vs 4.5% NCT02326272
- 35.8% vs 0.4% NCT02326298
- 39.8% vs 0.3% NCT02346240
- 31.2% vs 0.2% NCT02346240
- 53.8% vs 0.2% NCT03051217
- 46.6% vs 1.7% NCT00245765
- 39% vs 1.7% NCT00245765
- infliximab-qbtx (Ixifi)
- —Not reported
PASI 100
- certolizumab pegol
- —Not posted · NCT04123795
- infliximab-qbtx (Ixifi)
- —Not reported
sPGA 0/1
- certolizumab pegol
- 57.9% vs 4.2%+53.7 vs placeboNCT02326298
5 other results
- 47% vs 4.2% NCT02326298
- 66.7% vs 0% NCT03051217
- 52.7% vs 0% NCT03051217
- 72.4% vs 1.7% NCT00245765
- 52.5% vs 1.7% NCT00245765
- infliximab-qbtx (Ixifi)
- —Not reported
DLQI, change
- certolizumab pegol
- -10 vs -3.8−6.2 vs placeboNCT02326272
5 other results
- -10.2 vs -3.3 NCT02326298
- -6.8 vs -0.3 NCT03051217
- -10.4 vs -3.8 NCT02326272
- -9.3 vs -3.3 NCT02326298
- -6.8 vs -0.3 NCT03051217
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-qbtx (Ixifi): no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. certolizumab pegol: 4 of 4 rows · infliximab-qbtx (Ixifi): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol |
|---|---|
| Dropout rate | —400 mg Q2Wa NCT02326272 · Phase 3 show 20 more results—200 mg Q2W NCT02326272 · Phase 3 —400 mg Q2W NCT02326298 · Phase 3 —200 mg Q2W NCT02326298 · Phase 3 —400 mg Q2W NCT02346240 · Phase 3 —400 mg Q4W NCT02346240 · Phase 3 —200 mg Q2W NCT02346240 · Phase 3 —400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence —200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination —200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence 5.4%400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 5.9%200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 13.8%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 23.7%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —400 mg Q2Wa NCT02326272 · Phase 3 show 20 more results—200 mg Q2W NCT02326272 · Phase 3 —400 mg Q2W NCT02326298 · Phase 3 —200 mg Q2W NCT02326298 · Phase 3 —400 mg Q2W NCT02346240 · Phase 3 —400 mg Q4W NCT02346240 · Phase 3 —200 mg Q2W NCT02346240 · Phase 3 —400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence —200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination —200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg NCT00329303 · Phase 2 · registry result, not featured evidence —200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 0%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 1.7%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 8.1%400 mg Q2Wa NCT02326272 · Phase 3 show 20 more results14.1%200 mg Q2W NCT02326272 · Phase 3 11.4%400 mg Q2W NCT02326298 · Phase 3 7.4%200 mg Q2W NCT02326298 · Phase 3 12.4%400 mg Q2W NCT02346240 · Phase 3 11.4%400 mg Q4W NCT02346240 · Phase 3 9.1%200 mg Q2W NCT02346240 · Phase 3 9.4%400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence 2.8%200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination 2.8%200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence 6.6%All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence 0%400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 0%200 mg NCT00329303 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 8.8%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 400 mg Q2Wa nasopharyngitis 23.5% upper respiratory tract infection 12.1% psoriasis 8.1% NCT02326272 · Phase 3 show 17 more results200 mg Q2W nasopharyngitis 19.4% upper respiratory tract infection 11.2% sinusitis 7.6% NCT02326272 · Phase 3 400 mg Q2W nasopharyngitis 30.5% upper respiratory tract infection 15.6% headache 8.4% NCT02326298 · Phase 3 200 mg Q2W nasopharyngitis 28.7% upper respiratory tract infection 11.2% arthralgia 7.4% NCT02326298 · Phase 3 400 mg Q2W nasopharyngitis 16% (placebo 11.7%) upper respiratory tract infection 10.9% (placebo 10.2%) hypertension 5.8% (placebo 5.5%) NCT02346240 · Phase 3 400 mg Q4W arthralgia 6.8% (placebo 2.3%) blood creatine phosphokinase increased 6.8% (placebo 1.6%) nasopharyngitis 6.8% (placebo 11.7%) NCT02346240 · Phase 3 200 mg Q2W nasopharyngitis 15% (placebo 11.7%) upper respiratory tract infection 10.2% (placebo 10.2%) viral upper respiratory tract infection 6.2% (placebo 1.6%) NCT02346240 · Phase 3 400 mg Q2W nasopharyngitis 43.8% (placebo 23.1%) psoriasis 7.8% (placebo 23.1%) dermatitis contact 6.3% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 400 mg Q4W nasopharyngitis 30% (placebo 23.1%) back pain 10% (placebo 0%) dental caries 10% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 200 mg Q2W + 400 mg Q4W nasopharyngitis 34.7% (placebo 23.1%) psoriasis 11.1% (placebo 23.1%) eczema 6.9% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination 200 mg Q2W nasopharyngitis 31.9% (placebo 23.1%) psoriasis 11.1% (placebo 23.1%) eczema 6.9% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 43.4% (placebo 23.1%) psoriasis 10.7% (placebo 23.1%) eczema 7.4% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 400 mg headache 8.1% nasopharyngitis 8.1% asthenia 5.4% NCT00329303 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 14.7% psoriasis 11.8% arthralgia 5.9% NCT00329303 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.1% (placebo 17.2%) headache 14% (placebo 15.5%) bronchitis 7% (placebo 5.2%) NCT00245765 · Phase 2 · registry result, not featured evidence 200 mg headache 21.7% (placebo 15.5%) pruritus 11.7% (placebo 6.9%) arthralgia 8.3% (placebo 3.4%) NCT00245765 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 11 more results
show 1 more result
show 11 more results
show 1 more result
show 7 more results
show 5 more results
show 5 more results
show 3 more results
show 3 more results
show 4 more results
show 1 more result
show 3 more results
+ 11 further endpoints in the CSV export.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)
Result source: NCT03357471
infliximab-qbtx (Ixifi)
Marketed by Pfizer
NCT02222493 · Phase 3 · completed
This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.
Reported efficacy
Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)
Result source: NCT02222493
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | certolizumab pegol | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 | 51.1% vs 25.9%+25.2 vs placeboNCT0071723621 other results
| 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT0222249312 other results
|
| ACR50 | 61.8% vs 52.6%+9.2 vs placeboNCT0151979111 other results
| —Not reported |
| ACR70 | 51.3% vs 39.9%+11.4 vs placeboNCT015197919 other results
| —Not reported |
| DAS28-CRP remission | 16% vs 5.7%+10.3 vs placeboNCT00717236 | —Not reported |
| HAQ-DI, change | -1.0 vs -0.8−0.2 vs placeboNCT015197918 other results
| —Not reported |
| Modified Sharp score, change | 0.4 vs 1.6−1.2 vs placeboNCT014512036 other results
| —Not reported |
ACR20
- certolizumab pegol
- 51.1% vs 25.9%+25.2 vs placeboNCT00717236
21 other results
- 67.2% vs 14.9% NCT00791921
- 54.8% vs 23.9% NCT02151851
- 77.6% vs 28.6% NCT00791999
- 76.8% vs 28.6% NCT00791999
- 62.5% vs 28.6% NCT00791999
- 66.7% vs 27.5% NCT00993317
- 69% vs 61.5% NCT01519791
- 71.8% vs 24.7% NCT00791999
- 36.5% vs 15.3% NCT00674362
- 63.8% vs 11.4% NCT00791921
- 73.2% vs 24.7% NCT00791999
- 61.1% vs 24.7% NCT00791999
- 64.2% vs 37.5% NCT00993317
- 86.5% vs 74.7% NCT01521923
- 73.8% vs 74.7% NCT01521923
- 65.2% vs 44.9% NCT00580840
- 67.1% vs 44.9% NCT00580840
- 61.5% vs 0% NCT01147341
- 69.2% vs 71.4% NCT01500278
- 54.5% vs 62.5% NCT01147341
- 64.5% vs 60.8% NCT01500278
- infliximab-qbtx (Ixifi)
- 61.1% vs 63.5%vs Infliximab-EU Remicade (INX)NCT02222493
12 other results
- 64.8% vs 65.6% NCT02222493
- 57.7% vs 61.7% NCT02222493
- 52.5% vs 58.3% NCT02222493
- 32.4% vs 37.1% NCT02222493
- 63.3% vs 65.3% NCT02222493
- 60.8% vs 64.1% NCT02222493
- 73.6% vs 70.6% NCT02222493
- 76.9% vs 70.6% NCT02222493
- 71.1% vs 68.5% NCT02222493
- 69.2% vs 68.5% NCT02222493
- 71.1% vs 64.3% NCT02222493
- 70.6% vs 64.3% NCT02222493
ACR50
- certolizumab pegol
- 61.8% vs 52.6%+9.2 vs placeboNCT01519791
11 other results
- 80.2% vs 68.4% NCT01521923
- 36.5% vs 7.1% NCT02151851
- 26.6% vs 9.9% NCT00717236
- 20.8% vs 7.1% NCT00674362
- 43.2% vs 20% NCT00993317
- 25.9% vs 12.5% NCT00993317
- 71.4% vs 68.4% NCT01521923
- 52.2% vs 30.4% NCT00580840
- 50% vs 30.4% NCT00580840
- 27.3% vs 37.5% NCT01147341
- 19.2% vs 0% NCT01147341
- infliximab-qbtx (Ixifi)
- —Not reported
ACR70
- certolizumab pegol
- 51.3% vs 39.9%+11.4 vs placeboNCT01519791
9 other results
- 12.9% vs 2.8% NCT00717236
- 13.6% vs 0% NCT00993317
- 70.6% vs 60.8% NCT01521923
- 16.7% vs 2.7% NCT02151851
- 9.4% vs 3.1% NCT00674362
- 17.3% vs 2.5% NCT00993317
- 63.1% vs 60.8% NCT01521923
- 37.7% vs 15.9% NCT00580840
- 30% vs 15.9% NCT00580840
- infliximab-qbtx (Ixifi)
- —Not reported
DAS28-CRP remission
- certolizumab pegol
- 16% vs 5.7%+10.3 vs placeboNCT00717236
- infliximab-qbtx (Ixifi)
- —Not reported
HAQ-DI, change
- certolizumab pegol
- -1.0 vs -0.8−0.2 vs placeboNCT01519791
8 other results
- -0.5 vs -0.2 NCT02151851
- -0.4 vs -0.2 NCT00717236
- -0.3 vs -0.0 NCT00674362
- -0.5 vs -0.2 NCT00993317
- -0.5 vs -0.8 NCT01235598
- -0.6 vs -0.4 NCT00580840
- -0.7 vs -0.4 NCT00580840
- -0.6 vs -0.7 NCT01500278
- infliximab-qbtx (Ixifi)
- —Not reported
Modified Sharp score, change
- certolizumab pegol
- 0.4 vs 1.6−1.2 vs placeboNCT01451203
6 other results
- 0.2 vs 1.8 NCT01519791
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0.3 vs 0.9 NCT01451203
- infliximab-qbtx (Ixifi)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. certolizumab pegol: 5 of 5 rows · infliximab-qbtx (Ixifi): 3 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | certolizumab pegol Rows use multiple source trials | infliximab-qbtx (Ixifi) |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 81.3% (n=841)a,b,c NCT00175877 · Phase 3 3 other source trials74.2% (n=565) NCT00160641 · Phase 3 · registry result, not featured evidence 76.4% (n=140) @ 316wk NCT00160693 · Phase 3 · registry result, not featured evidence 57.2% (n=402) NCT00160693 · Phase 3 · registry result, not featured evidence | 68.3% (n=126) @ 78wk*d,a,b,c NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 86 participants as posted show 2 more doses77.8% (n=126) @ 78wk* NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted 75.9% (n=253) @ 78wk* NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 192 participants as posted |
| Dropout rate | —Q2We NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.3% NCT00175877 · Phase 3 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 31.1% NCT01443364 · Phase 4 · registry result, not featured evidence 47.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 49.3%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 3.7% NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 2.7%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2.4%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 4.2%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination 55.8% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 15.7%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 11.8%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 31.1% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 30.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 32.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 41.8%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14.3% NCT01235598 · Phase 3 · registry result, not featured evidence 26.7% NCT00843778 · Phase 3 · registry result, not featured evidence 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence 39% NCT00160641 · Phase 3 · registry result, not featured evidence 29.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 8.3% NCT00753454 · Phase 3 · registry result, not featured evidence 9.4% NCT00717236 · Phase 3 · registry result, not featured evidence 58.5% NCT00160693 · Phase 3 · registry result, not featured evidence 12.5%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 29.3%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 23.5%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 19.5%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 29.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 30.3% NCT04740814 · Phase 1 · registry result, not featured evidence | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Discontinued due to AEs | —Q2We NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 16.1% NCT00175877 · Phase 3 — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination — NCT01443364 · Phase 4 · registry result, not featured evidence 11.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 7.9%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence — NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 0.9%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 1.6%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 2.1%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination — NCT01519791 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination —Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 5.6% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 14%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 16.7%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 13.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 10.7% NCT01235598 · Phase 3 · registry result, not featured evidence 11.5% NCT00843778 · Phase 3 · registry result, not featured evidence — NCT01374971 · Phase 3 · registry result, not featured evidence 18% NCT00160641 · Phase 3 · registry result, not featured evidence 4.7%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT00753454 · Phase 3 · registry result, not featured evidence 3.9% NCT00717236 · Phase 3 · registry result, not featured evidence 24.1% NCT00160693 · Phase 3 · registry result, not featured evidence 6.3%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 6.9%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 8.2%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 3.7%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 9.1% NCT04740814 · Phase 1 · registry result, not featured evidence | —Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results—Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Serious AEs | 0%Q2We NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results0%Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.6% NCT00175877 · Phase 3 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.1% NCT01443364 · Phase 4 · registry result, not featured evidence 10.6%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 8.7%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 2.9% NCT01147341 · Phase 4 · registry result, not featured evidence 2.9%400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 7.1%200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence 1.8%Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 6.3%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence 6.3% NCT02151851 · Phase 3 · registry result, not featured evidence · combination 10.6% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 4.8%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 7.1%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 10.7% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 37.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 39.5%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 36.4%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence — NCT01235598 · Phase 3 · registry result, not featured evidence 19.2% NCT00843778 · Phase 3 · registry result, not featured evidence 0% NCT01374971 · Phase 3 · registry result, not featured evidence 35.3% NCT00160641 · Phase 3 · registry result, not featured evidence 9.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 3% NCT00753454 · Phase 3 · registry result, not featured evidence 6.1% NCT00717236 · Phase 3 · registry result, not featured evidence 45.8% NCT00160693 · Phase 3 · registry result, not featured evidence 5.2%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 11.2%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 5.9%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.9%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence | 5%Period 1: PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more results2.8%Period 2: INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.6%Period 2: PF-06438179/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 2.4%Period 3: INX/INX/PF-06438179 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 4.8%Period 3: INX/PF-06438179/PF-06438 NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 1.2%Period 3: PF-06438179/PF-06438179/ NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
| Most frequent reported AEs | show 34 more resultsnasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination influenza 11.4% arthralgia 6.8% bronchitis 5.3% NCT01443364 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 10.4% urinary tract infection 10.4% bronchitis 6% NCT01255761 · Phase 4 · registry result, not featured evidence urinary tract infection 10.6% upper respiratory tract infection 10% sinusitis 7.6% NCT01255761 · Phase 4 · registry result, not featured evidence upper respiratory infections 18.5% (placebo 0%) rash 11.8% (placebo 0%) bronchitis 8.8% (placebo 0%) NCT01147341 · Phase 4 · registry result, not featured evidence 400 mg upper respiratory tract infection 11.6% (placebo 14.5%) urinary tract infection 8.7% (placebo 10.1%) arthralgia 7.2% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination 200 mg upper respiratory tract infection 7.1% (placebo 14.5%) urinary tract infection 7.1% (placebo 10.1%) arthralgia 1.4% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 9.1% (placebo 5.3%) headache 7.3% (placebo 13.2%) nausea 5.5% (placebo 5.3%) NCT00993668 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 15.5% anaemia 5.6% liver function test abnormal 4.4% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 13.7% anaemia 5.3% liver function test abnormal 5.3% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 15.8% (placebo 13.3%) latent tuberculosis 7.6% (placebo 6.2%) liver function test abnormal 7% (placebo 3.5%) NCT02151851 · Phase 3 · registry result, not featured evidence · combination nausea 12.6% (placebo 10.1%) upper respiratory tract infection 10.9% (placebo 5.1%) urinary tract infection 7.3% (placebo 7.4%) NCT01519791 · Phase 3 · registry result, not featured evidence · combination Q2W urinary tract infection 6% (placebo 2.5%) nasopharyngitis 4.8% (placebo 6.2%) hypercholesterolaemia 2.4% (placebo 3.7%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination Q4W nasopharyngitis 10.2% (placebo 6.2%) hypercholesterolaemia 6.3% (placebo 3.7%) latent tuberculosis 5.5% (placebo 0%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 44% (placebo 34.4%) hepatic function abnormal 32.1% (placebo 30.6%) nausea 24.5% (placebo 19.1%) NCT01451203 · Phase 3 · registry result, not featured evidence · combination 400 mg nasopharyngitis 44.2% pharyngitis 16.3% bronchitis 14% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg rheumatoid arthritis 25% bronchitis 16.7% constipation 16.7% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 41.9% eczema 27.9% upper respiratory tract infection 20.9% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 38.2% eczema 18.2% pharyngitis 15.5% NCT00850343 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.2% diarrhoea 6.2% nasopharyngitis 6.2% NCT00843778 · Phase 3 · registry result, not featured evidence flare of rheumatoid arthritis 8.3% headache 8.3% injection site reaction 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16% hypertension 13.6% rheumatoid arthritis 13.4% NCT00160641 · Phase 3 · registry result, not featured evidence 200mg upper respiratory tract infection 14.1% (placebo 11.9%) nasopharyngitis 11.8% (placebo 9.5%) abdominal pain upper 5.9% (placebo 4.8%) NCT00993317 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 13.7% NCT00753454 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.3% (placebo 5.3%) headache 5.4% (placebo 5.3%) rheumatoid arthritis 4.4% (placebo 7.7%) NCT00717236 · Phase 3 · registry result, not featured evidence nasopharyngitis 35.1% upper respiratory tract infection 23.1% back pain 22.4% NCT00160693 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 10.4% (placebo 11.2%) upper respiratory tract infection 6.3% (placebo 4.1%) urinary tract infection 6.3% (placebo 5.1%) NCT00674362 · Phase 3 · registry result, not featured evidence 200mg nasopharyngitis 17.2% (placebo 14%) rash 8.6% (placebo 0%) eczema 5.2% (placebo 2.6%) NCT00791921 · Phase 3 · registry result, not featured evidence 400 mg nasopharyngitis 15.3% (placebo 11.7%) hepatic function abnormal 5.9% (placebo 5.2%) bronchitis 4.7% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 200 mg nasopharyngitis 13.4% (placebo 11.7%) pharyngitis 6.1% (placebo 3.9%) rash 4.9% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 100 mg hepatic function abnormal 11.1% (placebo 5.2%) nasopharyngitis 11.1% (placebo 11.7%) pharyngitis 6.9% (placebo 3.9%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 9.1% nausea 6.1% rheumatoid arthritis 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence | alanine aminotransferase increased 5.9% infusion related reaction 5.9% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 show 5 more resultsinfusion related reaction 4.2% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 infusion related reaction 2.9% alanine aminotransferase increased 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 alanine aminotransferase increased 0% infusion related reaction 0% NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
certolizumab pegol
show 20 more results
show 20 more results
show 9 more results
show 2 more results
show 1 more result
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 8 more results
show 7 more results
+ 100 further endpoints in the CSV export.
infliximab-qbtx (Ixifi)
+ 40 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: certolizumab pegol's landscape · infliximab-qbtx (Ixifi)'s landscape